Spike RBD Antibody (1038342) [Unconjugated]

In a functional flow cytometry test, Recombinant MERS-Cov Spike S1 Fc-tagged protein (10606-CV) binds to HEK293 human embryonic kidney cell line transfected with recombinant human CD26 and eGFP. (A) Binding is blocked by 50 µg/mL of Mouse Anti-MERS-Cov Spike RBD Monoclonal Antibody (Catalog # MAB107071) but not by (B) Mouse IgG2B Isotype Control (MAB0041). Protein binding was detected with Mouse Anti-Fc APC-conjugated Monoclonal Antibody (FAB110A). Staining was performed using our Staining Membrane-Associated Proteins protocol.

Spike RBD was detected in immersion fixed MERS RBD transfected cells using Mouse Anti-MERS-CoV Spike RBD Monoclonal Antibody (Catalog # MAB107071) at 8 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. Staining was performed using our protocol for Fluorescent ICC Staining of Non-adherent Cells.

• Reactivity: V
• Applications: B/N, ICC/IF
• Clone: 1038342
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

Spike RBD Antibody (1038342) [Unconjugated] Summary

• Immunogen: Chinese Hamster Ovary cell line CHO-derived MERS-CoV Spike RBD
  Glu367-Tyr606
  Accession # YP_007188579.1
• Specificity: Detects MERS-CoV Spike RBD in direct ELISAs.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Blockade of Receptor-ligand Interaction
  • Immunocytochemistry 8-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Spike RBD Antibody (1038342) [Unconjugated]

• Spike RBD

Background

MERS-CoV (also known as HCoV-EMC), which causes the Middle East Respiratory Syndrome (MERS), was first reported in Saudi Arabia in 2012 as a novel coronavirus (1). Coronaviruses are a family of viruses that are commonly comprised of a large plus-strand RNA genome and four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N). There are two well-known human coronavirus families that infect humans: Alpha coronaviruses which includes HCoV-229E and HCoV-NL63; beta coronaviruses that includes MERS-CoV, HCov-OC43, Severe Acute Respiratory Syndrome (SARS-CoV), and global pandemic Covid-19 (SARS-CoV2) (2). The MERS-CoV Spike Protein (S Protein) is a glycoprotein that mediates membrane fusion and viral entry, and it consists of two subunits, S1 and S2. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3). Located within the S1 subunit is the receptor binding domain (RBD). The RBD is responsible for the binding of MERS-CoV to dipeptidyl peptidase IV (DPP4, also known as human CD26) (4). The RBD of MERS-CoV shares 24% and 21% amino acid sequence (aa) identity with SARS-CoV RBD and SARS-Cov2 RBD, respectively. The low aa sequence identity is consistent with the finding that MERS-CoV and SARS-CoV bind different cellular receptors (4). The S1 subunit, especially the RBD region, of MERS-CoV was commonly targeted for vaccinations or antiviral therapies (5-7).

1. Zaki, A.M. et al. (2012) N. Engl. J. Med. 367:1814.
2. Ogimi, C. et al. (2020) J Pediatric Infect Dis Soc doi: 10.1093/jpids/piaa037.
3. Li, Y. et al. (2019) Engineering. 5:940.
4. Raj, V.S. et al. (2013) Nature 495:251.
5. Corti, D. et al. (2016) J. Infect. Public Health 9:231.
6. Tang, X.C. et al. (2014) Proc. Natl. Acad. Sci. USA 111:E2018.
7. Jiang, L. et al. (2014) Sci. Transl. Med. 6:234ra59.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • YP_007188579.1()